Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer

被引:20
|
作者
Jeremic, B
Shibamoto, Y
机构
[1] KYOTO UNIV, CHEST DIS RES INST, DEPT ONCOL, KYOTO 60601, JAPAN
[2] UNIV HOSP, DEPT ONCOL, KRAGUJEVAC, YUGOSLAVIA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1996年 / 34卷 / 02期
关键词
radiotherapy; hyperfractionation; interfraction interval; nonsmall cell lung cancer;
D O I
10.1016/0360-3016(95)02158-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the influence of interfraction interval in hyperfractionated radiotherapy (HFX RT) with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer. Methods and Materials: One hundred sixty-nine patients treated in a randomized study were retrospectively analyzed. Group I patients were treated by HFX RT with 1.2 Gy twice daily with a total dose of 64.8 Gy in 27 treatment days, while Groups II and III patients were treated by the same HFX RT and concurrent chemotherapy with carboplatin and etoposide (every week in Group II and every other week in Group III). Interfraction intervals of either 4.5-5 h or 5.5-6 h were used for each patient. Results: Patients treated with shorter interfraction intervals (4.5-5 h) had a better prognosis than those treated with longer intervals (5.5-6 h)(median survival: 22 vs. 7 months; 5-year survival rate: 27% vs. 0%, p = 0.00000). This phenomenon was observed in all treatment groups. Patients greater than or equal to 60 years of age, with Stage IIIA disease, or with previous weight loss less than or equal to 5% were treated more often with the shorter intervals than those < 60 years, with Stage IIIB disease, or with weight loss > 5%, respectively, but in all of these subgroups of patients, the shorter intervals were associated with a better prognosis. Multivariate analysis showed that the interfraction interval was an independent prognostic factor, together with sex, age, performance status, and stage, The shorter intervals were associated with an increased incidence of acute high grade toxicity, but not with an increase in late toxicity. Conclusion: Patients treated with shorter interfraction intervals (4.5-5 h) appeared to have a better survival than those treated with longer intervals (5.5-6 h). Prospective randomized studies are warranted to further investigate the influence of interfraction interval in HFX RT.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 50 条
  • [31] SCHEDULING OF CHEMOTHERAPY AND RADIOTHERAPY IN LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER
    BISHOP, JF
    LUNG CANCER, 1995, 12 : S53 - S61
  • [32] Concurrent hyperfractionated radiotherapy and chemotherapy for patients with limited small-cell lung cancer. Results from a single institution
    Sole Monne, Josep M.
    Garau, Miguel Macia
    Cambra Seres, Maria Jose
    Blanco Guerrero, Remei
    Montesions Munoz, Jesus
    Gallardo Diaz, Enrique
    Bestus Piulachs, Roma
    Mesia Nin, Ricard
    Monfa Binefar, Carlota
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2009, 14 (02) : 46 - 52
  • [33] A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer
    Jeremic, B
    Shibamoto, Y
    Milicic, B
    Milisavljevic, S
    Nikolic, N
    Dagovic, A
    Aleksandrovic, J
    Radosavljevic-Asic, G
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 44 (02): : 343 - 348
  • [34] High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: Unusual toxicity and promising early results
    King, SC
    Acker, JC
    Kussin, PS
    Marks, LB
    Weeks, KJ
    Leopold, KA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (03): : 593 - 599
  • [35] Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer
    Kaderbhai, C-G
    Coudert, B.
    Bertaut, A.
    Adnet, J.
    Favier, L.
    Lagrange, A.
    Peignaux-Casasnovas, K.
    Mettey, L.
    Tharin, Z.
    Foucher, P.
    Martin, E.
    CANCER RADIOTHERAPIE, 2020, 24 (04): : 279 - 287
  • [36] Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
    Tfayli, Arafat
    Al Assaad, Majd
    Fakhri, Ghina
    Akel, Reem
    Atwi, Hanine
    Ghanem, Hady
    El Karak, Fadi
    Farhat, Fadi
    Al Rabi, Kamal
    Sfeir, Pierre
    Youssef, Pierre
    Mansour, Ziad
    Assi, Hazem
    Haidar, Mohamad
    Abi Ghanem, Alain
    Khalifeh, Ibrahim
    Boulos, Fouad
    Mahfouz, Ramy
    Youssef, Bassem
    Zeidan, Youssef
    Bejjany, Rachelle
    Khuri, Fadlo
    CANCER MEDICINE, 2020, 9 (22): : 8406 - 8411
  • [37] Phase III study of csplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer
    Zhao, Qian
    Wang, Zhongtang
    Huang, Wei
    Wang, Qiang
    Yu, Shuzeng
    Zhou, Tao
    Han, Dan
    Wu, Zhenying
    Gong, Heyi
    Sun, Hongfu
    Zhang, Jian
    Wei, Yumei
    Li, Hongsheng
    Zhang, Zicheng
    Lin, Haiqun
    Li, Baosheng
    ONCOTARGET, 2016, 7 (07) : 8422 - 8431
  • [38] A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable nonsmall cell lung cancer: final report of an Australian multi-centre trial
    Ball, D
    Bishop, J
    Smith, J
    O'Brien, P
    Davis, S
    Ryan, G
    Olver, I
    Toner, G
    Walker, Q
    Joseph, D
    RADIOTHERAPY AND ONCOLOGY, 1999, 52 (02) : 129 - 136
  • [39] Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience
    Yilmaz, Ufuk
    Yilmaz, Ulku
    Yasar, Zehra
    Kirakli, Esra Korkmaz
    Ulger, Sukran
    Ozdogan, Yasemin
    Demirci, Nilgun Yilmaz
    Erol, Serhat
    Ozdogan, Ilker
    Sahin, Burcu
    Koksal, Deniz
    Akcay, Cimen
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 334 - 339
  • [40] A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer
    Yuan, Shuanghu
    Sun, Xindong
    Li, Minghuan
    Yu, Jinming
    Ren, Ruimei
    Yu, Yonghu
    Li, Jianbin
    Liu, Xiuqing
    Wang, Renben
    Li, Baosheng
    Kong, Li
    Yin, Yong
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (03): : 239 - 244